Dextropropoxyphene

Indications
 Oral
Mild to moderate pain
Adult: As hydrochloride: 65 mg 3-4 times daily. As napsilate: 100 mg 3-4 times daily.
Renal impairment: Dose reduction may be needed.
Hepatic impairment: Dose reduction may be needed.
Contraindications
 Hypersensitivity, chronic resp diseases, porphyria, pregnancy. Patients on MAOI treatment or within 2 wk of stopping treatment.
Warnings / Precautions
 Suicidal patients, hepatic or renal disease; lactation, elderly.
Adverse Reactions
 Dizziness, sedation, weakness; nausea, vomiting, constipation; rash, urticaria; visual disturbances; physiological dependence.
Potentially Fatal: Convulsions in long-term therapy. Cardiac conduction abnormalities and arrhythmias; liver impairment.
Overdose Reactions
 Symptoms: Coma, respiratory depression, circulatory collapse, pulmonary oedema, seizures, nephrogenic diabetes insipidus, ECG abnormalities. Death may occur as early within the 1st 15 minutes to 1 hr. Management: Intensive symptomatic and supportive therapy to be instituted immediately. IV naloxone may reverse intoxication. Induction of emesis or gastric lavage followed by activated charcoal helps to reduce absorption. Monitor blood gases, pH, electrolytes and ECG. Dialysis is unlikely to be useful.
Drug Interactions
 Inhibits hepatic metabolism of benzodiazepines, β-blockers, carbamazepine, phenytoin and warfarin. Increased risk of toxicity when co-administered with ritonavir. Potentiation of depressant effects when used with alcohol or CNS depressants.
Potentially Fatal: Accidental or intentional overdosage fatal (especially if combined with alcohol, and analgesics e.g. paracetamol and aspirin).
See Below for More dextropropoxyphene Drug Interactions
Food Interactions
 Absorption decreased.
Mechanism of Actions
 Dextropropoxyphene is a relatively weak opioid analgesic which binds to mu- and kappa-receptors in order to block pain perception in the cerebral cortex. This results in inhibiton of pain sensation flow into high centers.
Absorption: Readily absorbed from the GI tract; napsilate form more slowly absorbed than the HCl (oral); peak plasma concentrations after 1-2 hr.
Distribution: Concentrated in the liver, lungs and brain; crosses the placenta and small amounts enter breast milk. Protein-binding: 80%.
Metabolism: Hepatic, to nordextropropoxyphene (norpropoxyphene); undergoes 1st-pass metabolism.
Excretion: Urine (as metabolites). Elimination half-life: 6-12 hr (dextropropoxyphene), 30-36 hr (norpropoxyphene).
Administration
 May be taken with or without food.
Storage Conditions
 Oral: Store at 15-30°C.
ATC Classification
 N02AC04 - dextropropoxyphene ; Belongs to the class of diphenylpropylamine derivative opioids. Used to relieve pain.
Storage
 Oral: Store at 15-30°C.
Available As
  • Dextropropoxyphene 30 mg
  • Dextropropoxyphene 32 mg
  • Dextropropoxyphene 32.5 mg
  • Dextropropoxyphene 32.5mg
  • Dextropropoxyphene 33 mg
  • Dextropropoxyphene 65 mg
  • Dextropropoxyphene 70 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Dextropropoxyphene


    Dextropropoxyphene Containing Brands

    We are Developing Our database, More results coming soon.

    Dextropropoxyphene is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Dextropropoxyphene

    We are Developing Our database, More results coming soon.